Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children

被引:70
作者
Haralambous, E
Hibberd, ML
Hermans, PWM
Ninis, N
Nadel, S
Levin, M
机构
[1] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Dept Paediat, Fac Med, London W2 1PG, England
[2] St Marys Hosp, Paediat Intens Care Unit, London, England
[3] Univ Rotterdam, Med Ctr, Erasmus MC, Sophia Childrens Hosp,Dept Paediat, Rotterdam, Netherlands
关键词
plasminogen-activator-inhibitor-1; meningococcal; sepsis; pediatric; genetics; severity;
D O I
10.1097/01.CCM.0000100122.57249.5D
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective. Meningococcal sepsis invariably is associated with coagulopathy. We have previously reported an association between mortality rate in meningococcal disease and the functional 4G/5G promoter polymorphism of the plasminogen-activator-inhibitor (PAI)-1 gene in a small patient cohort. In a much larger cohort, we aimed to confirm these results and further investigate the role of the 4G/5G polymorphism in determining susceptibility, outcome, and complications of disease. Design: Susceptibility was investigated in two separate studies, a case-control study and a family-based transmission study, each test using a separate patient cohort. Severity was investigated using clinical diagnosis, the presence of vascular complications, Pediatric Risk of Mortality (PRISM)-predicted morality, and actual mortality. Setting. University hospital and laboratories. Subjects: Subjects were 510 UK pediatric patients, 210 parents of patients, and 155 UK Caucasian controls. Interventions., DNA extraction and 4G/5G PAI-1 genotyping was carried out using published techniques. Measurements and Main Results: Predicted mortality distribution differed significantly between genotypes (p = .05) with a significantly higher median PRISM in the 4G/4G (41.1%) than the 4G/5G (23.4%) and 5G/5G (19.0%) genotyped patients combined (p = .02). Actual mortality rate was significantly associated with both genotype (chi-square = 14.8, p = .001) and allele frequencies (chi-square = 14.0, p < .0001), with more deaths in the 4G/4G (28.4%) than the 4G/5G and 5G/5G genotyped patients combined (14.9%; chi-square = 7.9; p = .005; risk ratio, 1.9; 95% confidence interval, 1.2-3.0). Logistic regression indicated a 40% and 91% reduction in the odds of dying if a patient was either 4G/5G or 5G/5G, respectively, in comparison to a 413 homozygous patient. When analyzed by clinical diagnosis, the association with death was found only in the sepsis group (chi-square = 18.7, p < .0001; risk ratio, 2.7; 95% confidence interval, 1.6-4.6). In survivors of disease, a significantly higher proportion of 4G/4G patients suffered from vascular complications (chi-square = 6.7, p = .03; risk ratio, 2.4; 95% confidence interval, 1.1-5.0). The 4G/5G polymorphism was not associated or linked with susceptibility (case-control result, p = .6; family-based transmission study results, p = .2). Conclusions. This study confirms that Caucasian pediatric patients carrying the functional PAI-1 4G/4G genotype are at an increased risk of developing vascular complications and dying from meningococcal disease.
引用
收藏
页码:2788 / 2793
页数:6
相关论文
共 55 条
[31]   Mechanisms of disease: Plasminogen-activator inhibitor type 1 and coronary artery disease. [J].
Kohler, HP ;
Grant, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (24) :1792-1801
[32]  
Linton SM, 1999, CLIN EXP IMMUNOL, V118, P189
[33]   REGULATION OF THE TISSUE FACTOR GENE [J].
MACKMAN, N .
FASEB JOURNAL, 1995, 9 (10) :883-889
[34]   ABNORMALLY HIGH CIRCULATION LEVELS OF TISSUE-PLASMINOGEN ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN PATIENTS WITH A HISTORY OF ISCHEMIC STROKE [J].
MARGAGLIONE, M ;
DIMINNO, G ;
GRANDONE, E ;
VECCHIONE, G ;
CELENTANO, E ;
CAPPUCCI, G ;
GRILLI, M ;
SIMONE, P ;
PANICO, S ;
MANCINI, M .
ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (11) :1741-1745
[35]   Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients [J].
Menges, T ;
Hermans, PWM ;
Little, SG ;
Langefeld, T ;
Böning, O ;
Engel, J ;
Sluijter, M ;
de Groot, R ;
Hempelmann, G .
LANCET, 2001, 357 (9262) :1096-1097
[36]  
NADEL S, 1995, MENINGOCOCCAL DIS, P207
[37]   CLONING AND SEQUENCE OF A CDNA CODING FOR THE HUMAN BETA-MIGRATING ENDOTHELIAL-CELL-TYPE PLASMINOGEN-ACTIVATOR INHIBITOR [J].
NY, T ;
SAWDEY, M ;
LAWRENCE, D ;
MILLAN, JL ;
LOSKUTOFF, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (18) :6776-6780
[38]   ENDOTHELIAL PLASMINOGEN-ACTIVATOR INHIBITOR (PAI) - A NEW MEMBER OF THE SERPIN GENE FAMILY [J].
PANNEKOEK, H ;
VEERMAN, H ;
LAMBERS, H ;
DIERGAARDE, P ;
VERWEIJ, CL ;
VANZONNEVELD, AJ ;
VANMOURIK, JA .
EMBO JOURNAL, 1986, 5 (10) :2539-2544
[39]   PLASMINOGEN-ACTIVATOR INHIBITOR IN THE BLOOD OF PATIENTS WITH CORONARY-ARTERY DISEASE [J].
PARAMO, JA ;
COLUCCI, M ;
COLLEN, D ;
VANDEWERF, F .
BRITISH MEDICAL JOURNAL, 1985, 291 (6495) :573-574
[40]   PEDIATRIC RISK OF MORTALITY (PRISM) SCORE [J].
POLLACK, MM ;
RUTTIMANN, UE ;
GETSON, PR .
CRITICAL CARE MEDICINE, 1988, 16 (11) :1110-1116